Pregnancy, Childbirth, and HIVFeatures

Tsepamo Study Provides Critical Update on Neural Tube Defects and Dolutegravir

#4 in TheBodyPro's Top 10 HIV Clinical Developments of 2019

Dolutegravir and Pregnancy photo illo
Photo illustration: Remedy Health Media; Background and paper tear: iStock

    Original Tsepamo results: 9th IAS Conference on HIV Science. (2017). "Dolutegravir / tenofovir / emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe as efavirenz / tenofovir / emtricitabine (EFV/TDF/FTC) in nationwide birth outcomes surveillance in Botswana."

    Expanded Tsepamo results: 10th IAS Conference on HIV Science. (2019). "Neural tube defects by antiretroviral and HIV exposure in the Tsepamo Study, Botswana."

    David Alain Wohl, M.D.

    David Alain Wohl, M.D.

    David Alain Wohl, M.D., is a professor at the University of North Carolina, site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AETC, and co-director of HIV services for the NC state prison system.